Exchange: NASDAQ·Updated 03:28 PM EST

VCEL News

News
all
press releases
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.
Zacks
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
Novartis wins FDA approval for Cosentyx in adults with PMR, backed by phase III data showing sustained remission and steroid-sparing benefits.
Zacks
More News
JNJ's $2.2 billion Ollin acquisition adds a phase III eye disease candidate to its pipeline, with Blackstone providing $750 million to fund the development.
Zacks
NVS' Cosentyx gains a positive CHMP recommendation for adolescents with moderate to severe HS, potentially expanding treatment options in Europe.
Zacks
Aberdeen Group plc raised its stake in Vericel Corporation (NASDAQ:VCEL - Free Report) by 204.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,164,250 shares of the biotechnology company's st...
MarketBeat
PFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.
Zacks
Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.
Zacks
Vericel Corporation (VCEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
(RTTNews) - Advanced therapies company Vericel Corp. (VCEL) on Thursday reported a surge in third-quarter profit, driven by higher sales compared to a year earlier...
Nasdaq News: Markets
Vericel (VCEL) delivered earnings and revenue surprises of +1,250.00% and +9.03%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.